Dr Reddys launches OTC brand equivalent of Mucinex D ER tablets to treat phlegm

The Mucinex D brand and store brands had combined US sales of approximately USD 71 million MAT (moving annual turnover) for the most recent 12 months ending May 2019, the release said quoting market reports, the release said.

Hyderabad: Dr Reddys Laboratories Ltd (DRL) recently announced the launch of an over-the-counter (OTC) store-brand equivalent of Mucinex D extended-release tablets in two strengths.

The OTC Guaifenesin and Pseudoephedrine HCl is used to help loosen phlegm (mucus) and thin bronchial secretions to rid the bronchial passageways of bothersome mucus, a press release from the company said.

"We are excited to bring first to the market the store-brand equivalent of Mucinex D maximum strength extended-release tablets. The launch illustrates our continued commitment to the OTC business and our growing portfolio in the cough, cold and allergy category," Milan Kalawadia, senior vice-president and head of US (OTC and speciality Rx divisions), Dr Reddys, said in the release.

Read Also: Dr Reddy's Laboratories to buy IP rights of fondaparinux for $17.5 million

The Mucinex D brand and store brands had combined US sales of approximately USD 71 million MAT (moving annual turnover) for the most recent 12 months ending May 2019, the release said quoting market reports, the release said.

The OTC product is available as Guaifenesin 600 mg and Pseudoephedrine HCl 60 mg and Guaifenesin 1200 mg and Pseudoephedrine HCl 120 mg strengths, it said.

Dr Reddy's OTC Guaifenesin 1200 mg and Pseudoephedrine HCl 120 mg is available in 24-count packages while OTC Guaifenesin 600 mg and Pseudoephedrine HCl 60 mg is available in 18- and 36-count packages.

Dr Reddy's Labs offers a portfolio of products and services including APIs, custom pharmaceutical services, generics, biosimilars and differentiated formulations. The major therapeutic areas of focus are gastrointestinal, cardiovascular, diabetology, oncology, pain management and dermatology.

Read Also: Awaiting USFDA response on remediation efforts of 3 units: Dr Reddys Laboratories